Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Dermatologikum Berlin, Berlin, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:5City/State/Province:Berlin
Treatments:ImmunotherapyHospital:Dermatologikum Berlin
Drugs:Journal:Link
Date:Aug 2014

Description:

Patients:
This phase 2 study involved 32 previously treated metastatic melanoma patients with an average age of 65.4 years; 53.1% were male.

Treatment:
Patients received aviscumine, an immunotherapy agent that stimulates the immune system and causes cancer cell death.

Toxicities:
There were two reported study-related deaths due to respiratory distress and cardiac failure. Grade 1-2 application site reactions and grade 3 pruritus (itchy skin) were also reported.

Results:
The median overall survival was 11 months.

Support:
This study was supported by CYTAVIS BioPharma, makers of the study drug.

Correspondence: Dr. Hans Lentzen; email: [email protected]



Back